Headline results for the third quarter:
|Revenue||JPY 186.8 billion ($1.7 billion)||Versus JPY 157.1 billion ($1.4 billion)|
|Profit||JPY 46.5 billion ($428.9 million)||Versus JPY 7.4 billion ($68 million)|
Note: All changes are versus the prior-year period unless otherwise stated
What the company said:
Eisai attributed the quarter's revenue increase mainly to the cancer drug Lenvima demonstrating "significant growth continuously, absorbing the factors that contribute to decrease in revenue including transfer of [our] generic pharmaceutical subsidiary in April 2019." The company noted that it also recorded milestone payments of JPY 16 billion from Merck & Co. as revenue.
Neurology sales: JPY 48.8 billion ($449.7 million), up from JPY 47.7 billion ($439.6 million)
Fycompa: JPY 6.9 billion ($64 million), up from JPY 5.1 billion ($47 million)
Belviq: JPY 1.4 billion ($13 million), down from JPY 2 billion ($18 million)
Oncology sales: JPY 43.4 billion ($399.4 million), up from JPY 33.9 billion ($312.7 million)
Lenvima: JPY 30 billion ($276.7 million), up from JPY 18.9 billion ($174.4 million) in the year-ago period
Halaven: JPY 9.9 billion ($91 million), down from JPY 10.9 billion ($100.6 million) in the year-ago period
Eisai continues to expect sales for the fiscal year ending March 31 to be JPY 680 billion ($6.3 billion), reflecting year-on-year growth of 5.8%, with profit now forecast to rise 53.4% to JPY 102 billion ($940 million).
The Japanese drugmaker also reiterated recent comments made by partner Biogen that the latter company would be working to complete a regulatory filing for the jointly developed Alzherimer's disease drug aducanumab in the US "as soon as possible," without providing specifics. In October, Biogen said it planned to file for US approval of the once-failed drug in early 2020 based on a new analysis of data, months after ending two trials that had shown aducanumab was unlikely to benefit patients.
To read more Top Story articles, click here.